两剂和三剂COVID-19 mRNA疫苗在奥密克戎前时代针对感染、症状和严重程度的效果:时间依赖性梯度
在卡塔尔开展的国家匹配检测阴性病例对照研究,纳入238896份PCR阳性检测和6533739份PCR阴性检测,评估BNT162b2和mRNA-1273疫苗对无症状、有症状、重症、危重症和死亡COVID-19的有效性。两剂BNT162b2对无症状感染有效性75.6%(95%CI:73.6-77.5),对有症状感染76.5%(95%CI:75.1-77.9),对重症、危重症和死亡均超过90%。接种第二剂后181至270天,对无症状和有症状感染的有效性降至40%以下,但对重症、危重症和死亡的有效性持续较高,且不同疫苗类型和剂次模式呈现相似模式。
要点
- 两剂BNT162b2对无症状感染有效性75.6%,对有症状感染76.5%。
- 对重症、危重症和死亡COVID-19的有效性均超过90%。
- 接种第二剂后181至270天,对无症状和有症状感染的有效性降至40%以下。
核心结论
- 疫苗有效性存在梯度,与感染症状和严重程度相关,对有症状和重症病例提供更高保护。
- 随着最后一剂疫苗接种后免疫力减弱,这种梯度随时间加剧。
- 这些模式似乎与疫苗类型或是否涉及基础免疫系列或加强针无关。
研究设计与样本
- 在卡塔尔开展的国家匹配检测阴性病例对照研究,研究时间为2021年1月1日至2021年12月18日。
- 样本包括238896份PCR阳性检测和6533739份PCR阴性检测。
- 数据来源包括卡塔尔COVID-19实验室检测、疫苗接种、住院和死亡的国家数据库。
主要发现
- 两剂BNT162b2对无症状感染的有效性为75.6%(95%CI:73.6-77.5),对有症状感染为76.5%(95%CI:75.1-77.9)。
- 对重症、危重症和死亡COVID-19感染的有效性均超过90%。
- 接种第二剂后立即,无症状、有症状、重症、危重症和死亡COVID-19均表现出相似的高有效性。
- 接种第二剂后181至270天,对无症状和有症状感染的有效性降至40%以下,而对重症、危重症和死亡COVID-19的有效性持续较高。
- 对死亡COVID-19的估计值常具有较宽的95%置信区间;三剂BNT162b2接种以及两剂和三剂mRNA-1273接种观察到类似模式。
关键数值与推荐
- 两剂BNT162b2对无症状感染有效性75.6%(95%CI:73.6-77.5)。
- 两剂BNT162b2对有症状感染有效性76.5%(95%CI:75.1-77.9)。
- 对重症、危重症和死亡COVID-19感染的有效性均超过90%。
- 接种第二剂后181至270天,对无症状和有症状感染的有效性降至40%以下。
临床怎么用
- 原文未据此给出推荐。
局限性
- 对死亡COVID-19的估计值常具有较宽的95%置信区间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccines were developed and deployed to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This study aimed to characterize patterns in the protection provided by the BNT162b2 and mRNA-1273 mRNA vaccines against a spectrum of SARS-CoV-2 infection symptoms and severities. METHODS: A national, matched, test-negative, case-control study was conducted in Qatar between January 1 and December 18, 2021, utilizing a sample of 238,896 PCR-positive tests and 6,533,739 PCR-negative tests. Vaccine effectiveness was estimated against asymptomatic, symptomatic, severe coronavirus disease 2019 (COVID-19), critical COVID-19, and fatal COVID-19 infections. Data sources included Qatar's national databases for COVID-19 laboratory testing, vaccination, hospitalization, and death. RESULTS: Effectiveness of two-dose BNT162b2 vaccination was 75.6% (95% CI: 73.6-77.5) against asymptomatic infection and 76.5% (95% CI: 75.1-77.9) against symptomatic infection. Effectiveness against each of severe, critical, and fatal COVID-19 infections surpassed 90%. Immediately after the second dose, all categories-namely, asymptomatic, symptomatic, severe, critical, and fatal COVID-19-exhibited similarly high effectiveness. However, from 181 to 270 days post-second dose, effectiveness against asymptomatic and symptomatic infections declined to below 40%, while effectiveness against each of severe, critical, and fatal COVID-19 infections remained consistently high. However, estimates against fatal COVID-19 often had wide 95% confidence intervals. Analogous patterns were observed in three-dose BNT162b2 vaccination and two- and three-dose mRNA-1273 vaccination. Sensitivity analyses confirmed the results. CONCLUSION: A gradient in vaccine effectiveness exists and is linked to the symptoms and severity of infection, providing higher protection against more symptomatic and severe cases. This gradient intensifies over time as vaccine immunity wanes after the last vaccine dose. These patterns appear consistent irrespective of the vaccine type or whether the vaccination involves the primary series or a booster.
引用
- Sukik L, Chemaitelly H, Ayoub HH, et al. Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient. Vaccine. 2024. PMID: 38616439. doi:10.1016/j.vaccine.2024.04.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。